Vitamin K2 does not appear to be harmful to your kidneys, based on the available clinical evidence. Across multiple randomized trials in people with chronic kidney disease, vitamin K2 supplementation consistently improved markers of vitamin K status without causing kidney damage. The picture is more nuanced than a clean bill of health, though, because the research also has not shown that K2 actively protects kidney function either, and a couple of small studies flagged modest declines in one kidney marker that deserve a closer look.
Why This Question Keeps Coming Up
The concern about vitamin K2 and kidney health usually comes from one of two directions. The first is people with healthy kidneys who worry that any fat-soluble vitamin might accumulate and cause organ damage, the way excess vitamin A or vitamin D can. The second, larger group includes people who already have chronic kidney disease and wonder whether supplementing K2 could make things worse or interact with their medications. Both concerns are reasonable, but neither is supported by strong evidence of harm.
People with chronic kidney disease are actually more likely to be deficient in vitamin K than the general population. Their restricted diets (low in leafy greens due to potassium limits, low in dairy and fermented foods) contribute to this shortfall, and impaired recycling of vitamin K in the body may compound the problem.1PubMed Central. Vitamin K in Chronic Kidney Disease This widespread deficiency is partly what has driven researchers to study whether supplementing vitamin K2 could help kidney disease patients, not because anyone expected it to hurt them, but because it seemed like an obvious gap to fill.
How Vitamin K2 Relates to Calcification
To understand why vitamin K2 even enters the kidney conversation, you need to know what it does in the body. Vitamin K2 serves as a cofactor for activating certain proteins through a chemical modification. One of the most important of these proteins is Matrix Gla Protein, or MGP. When MGP is properly activated, it grabs free calcium floating around in your bloodstream and prevents it from depositing in soft tissues like blood vessel walls and organs.2PubMed Central. Vitamin k dependent proteins and the role of vitamin k2 in the modulation of vascular calcification: a review Without enough vitamin K2, MGP stays inactive, and calcium can end up in places it does not belong.
This matters enormously for people with kidney disease, because vascular calcification is one of the leading causes of cardiovascular death in that population. The kidneys normally help regulate calcium and phosphorus balance, so when they falter, calcification risk goes up. Researchers saw vitamin K2 as a potential way to activate the body’s natural braking system on that process. The theory was sound. The clinical results, as you will see, have been mixed.
What the Clinical Trials Actually Show About Kidney Function
A 2025 scoping review pulled together nine interventional studies examining vitamin K supplementation in people with kidney disease. The findings were consistent on one front: supplementation reliably lowered levels of dp-ucMGP, the inactive form of MGP, which signals that the vitamin was being absorbed and doing its biochemical job. But when researchers looked at actual kidney function markers like estimated glomerular filtration rate (eGFR), creatinine, and proteinuria, there was no sign of improvement. Two studies actually found a statistically significant rise in creatinine after the intervention period, which could indicate a slight worsening of kidney function.3PubMed Central. The Role of Vitamin K Deficiency in Chronic Kidney Disease—A Scoping Review
Before that finding triggers alarm, some context helps. A rise in creatinine can reflect many things beyond actual kidney damage: changes in muscle mass, hydration status, or even shifts in diet during a trial. The review’s authors noted that no studies found any clear tendency toward improved renal endpoints, but they also did not characterize the creatinine increases as evidence of toxicity. The overall picture is one of neutrality toward kidney function, not harm, and not protection either. If vitamin K2 were genuinely toxic to kidneys, you would expect to see consistent damage signals across multiple trials. That pattern does not exist.
Vascular Benefits in Kidney Disease Patients
Where vitamin K2 supplementation has shown more promising signals is in vascular health, which matters because cardiovascular disease is the number-one killer of people on dialysis or with advanced kidney disease. In a trial of kidney transplant recipients, eight weeks of menaquinone-7 (the most studied form of K2) supplementation was associated with a roughly 14 percent reduction in a measure of arterial stiffness, and this improvement tracked independently with the reduction in inactive MGP.4PubMed. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial A separate double-blind, placebo-controlled trial in vitamin K-deficient transplant recipients found that those who received K2 held their arterial stiffness steady while the placebo group got measurably stiffer over the study period.5American Journal of Transplantation. Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients
Not all trials have been this encouraging. A larger randomized controlled trial called K4Kidneys found no differences in pulse wave velocity, blood pressure, or other cardiovascular markers after 12 months of vitamin K supplementation. An updated meta-analysis conducted alongside that trial also showed no overall effect of vitamin K on vascular stiffness or calcification measures.6PubMed Central. Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial Meanwhile, a nine-month trial in patients with stage 3-5 CKD found that K2 may have slowed the progression of atherosclerosis without significantly affecting calcification itself.7PubMed. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5
The honest takeaway is that vitamin K2 reliably corrects deficiency biomarkers in kidney patients, sometimes improves measures of arterial health, but has not yet proven itself as a game-changer for hard clinical endpoints like heart attacks or death. None of this evidence points to kidney harm.
Vitamin K2 and Kidney Stones
A separate concern some people have is whether vitamin K2 could promote kidney stones. The logic runs that since K2 is involved in calcium metabolism, it might somehow push calcium into the kidneys. The evidence actually suggests the opposite mechanism. Vitamin K2 activates MGP, which sequesters free calcium and prevents it from depositing in soft tissues, including the kidneys. In animal studies, rats treated with vitamin K2 for six weeks showed reduced crystal deposition compared with untreated rats. And in human observational data, higher levels of the inactive form of MGP (indicating vitamin K deficiency) were associated with increased risk of stone formation, not lower risk.8PubMed Central. Vitamins as regulators of calcium-containing kidney stones — new perspectives on the role of the gut microbiome
This does not mean vitamin K2 is a proven kidney stone preventive. The human data on this is observational and the animal work is preliminary. But if your worry is specifically about stones, the biological mechanism goes in the direction of protection rather than risk. Being vitamin K deficient leaves more free calcium floating around with fewer proteins available to manage it, and that is the scenario more likely to feed stone formation.
The Warfarin Problem
The one genuinely serious safety concern around vitamin K2 has nothing to do with your kidneys directly. It is about drug interactions, specifically with warfarin and other vitamin K antagonist anticoagulants. Warfarin works by blocking vitamin K’s role in the clotting cascade. If you take supplemental vitamin K2, you can partially or fully counteract warfarin’s blood-thinning effect, which can be dangerous for people who need that anticoagulation to prevent strokes or blood clots. In animal models, even moderate doses of K2 reversed warfarin’s effect on clotting time, and high doses effectively neutralized it.9PubMed. Interaction of warfarin and vitamin K2 on arterial thrombotic tendency using a rat aorta loop model
This interaction is well known and clinically meaningful. If you are on warfarin (or acenocoumarol, another vitamin K antagonist sometimes used in Europe), do not start vitamin K2 supplements without your doctor adjusting your anticoagulant dose and monitoring your INR closely. This is the single biggest real-world risk of K2 supplementation, and it applies regardless of your kidney status. Newer direct oral anticoagulants like rivaroxaban and apixaban do not work through the vitamin K pathway, so this concern does not apply to those medications.
There is a bitter irony here for kidney patients on warfarin. Warfarin antagonism of vitamin K is associated with more than triple the odds of developing calciphylaxis, a rare but devastating condition where calcium deposits cause painful, necrotic skin lesions. Vitamin K deficiency is common in dialysis patients regardless of warfarin use, making this population especially vulnerable.10PubMed Central. Successful treatment of calciphylaxis with vitamin K in a patient on haemodialysis Some clinicians have begun using vitamin K supplementation as part of calciphylaxis treatment, essentially trying to reactivate the MGP that warfarin has been suppressing. But managing a patient who needs both anticoagulation and vitamin K is a tightrope walk that belongs firmly in the hands of a specialist.
How Phosphate Binders Can Interfere
People with advanced kidney disease often take phosphate binders with meals to keep their blood phosphorus levels in check. These medications can interact with vitamin K2 in a way most patients and even some clinicians do not think about: certain binders physically bind vitamin K2 in the gut, reducing the amount you actually absorb. Lab testing showed that calcium acetate/magnesium carbonate strongly bound vitamin K2 regardless of whether phosphate was also present. Calcium carbonate showed significant binding in the presence of phosphate. On the other hand, sucroferric oxyhydroxide and sevelamer carbonate did not significantly bind K2.11PubMed Central. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study
If you are a kidney patient taking both a phosphate binder and a vitamin K2 supplement, the type of binder matters. Calcium-based binders are the worst offenders for K2 absorption. Taking the supplement at a different time of day from your binder, or discussing a switch to a non-calcium-based binder with your nephrologist, could make the difference between getting the K2 into your bloodstream and having it pass right through. This is one of those practical details that gets lost between the supplement aisle and the pharmacy counter.
Safety Limits and Dosing
For people with healthy kidneys, vitamin K2 has an unusually clean safety profile among fat-soluble vitamins. Multiple regulatory bodies, including the Institute of Medicine, the European Commission, the UK Expert Group on Vitamins and Minerals, and the WHO, have reviewed the evidence and declined to set a tolerable upper intake level for any form of vitamin K, because no adverse effects have been demonstrated even at doses well above normal dietary intake. The UK’s Expert Group did set a guidance level of 1,000 micrograms per day, and the Council for Responsible Nutrition set a supplemental upper limit of 10,000 micrograms per day.12Scientific Reports. Safety evaluation of vitamin K2 (menaquinone-7) via toxicological tests Most commercially available K2 supplements contain between 100 and 200 micrograms, so they fall far below even the most conservative safety threshold.
For people with existing kidney disease, the safety data is also reassuring in the sense that no trial has reported serious adverse events attributable to vitamin K2. The doses tested in kidney disease trials have typically ranged from 90 to 400 micrograms of MK-7 daily. Hemodialysis patients who received MK-7 showed improved MGP activation with good tolerability, and MK-7 outperformed phytomenadione (vitamin K1) in one head-to-head comparison.13The Egyptian Journal of Internal Medicine. Different vitamin K forms in hemodialysis patients: a simple dietary supplement to battle vascular calcification—randomized controlled trial Pediatric hemodialysis patients given vitamin K2 along with native vitamin D showed beneficial effects on calcification regulators without reported harm.14European Journal of Clinical Nutrition. The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial
Testing for Vitamin K Deficiency
Unlike vitamin D, vitamin K status is not part of routine blood work, and most people (including kidney patients) have no idea whether they are deficient. The most clinically useful marker is dp-ucMGP, the inactive form of Matrix Gla Protein. Higher levels indicate poorer vitamin K status because less of the protein has been activated. Research has established reference intervals for this marker in healthy adults, and it has shown promise as a biomarker for diabetic kidney disease, performing comparably to the standard urine albumin-to-creatinine ratio for detecting kidney function decline in people with diabetes.15PubMed Central. Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential
The dp-ucMGP test is not yet widely available outside of research settings, though some specialized laboratories offer it. Patients with advanced CKD are almost certainly deficient to some degree based on population-level data, which has led some researchers to argue that supplementation could be justified empirically in this group even without individual testing.16Kidney International. Vitamin K and cardiovascular complications in chronic kidney disease patients That said, the lack of proven benefit on hard clinical endpoints means this remains a judgment call between a patient and their nephrologist, not a universal recommendation.
Where Most of Your Vitamin K2 Comes From
Before reaching for a supplement, it is worth knowing that vitamin K2 is naturally produced by bacteria in fermented foods. The richest dietary source by far is natto, a traditional Japanese fermented soybean product that contains dramatically more K2 per serving than any other food. Certain aged cheeses, fermented soy products, and some fermented vegetables also provide meaningful amounts, with the specific bacteria involved in fermentation determining how much K2 ends up in the final product.17PubMed Central. Vitamins formed by microorganisms in fermented foods: effects on human vitamin status—a systematic narrative review For people without kidney disease, incorporating fermented foods into the diet may be a simpler starting point than supplementation. For those on restricted diets because of kidney disease, supplements become more practical since many K2-rich foods are also high in potassium, phosphorus, or sodium.